Acelyrin Enters The Spotlight As NASDAQ Debut Dawns
Raising $540m
The US biotech intends to use the proceeds from its upcoming IPO to advance lead candidate izokibep, an interleukin-17A inhibitor that is showing potential as a treatment for hidradenitis suppurativa.
